Elsevier

Epilepsy Research

Volume 22, Issue 3, November 1995, Pages 235-246
Epilepsy Research

Conference review
Progress report on new antiepileptic drugs A summary of the Second Eilat Conference

https://doi.org/10.1016/0920-1211(95)00054-2Get rights and content

Abstract

The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, ‘Still Searching for the Magic Bullet’.

References (11)

  • M.J. Brodie

    Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy

    Lancet

    (1995)
  • M.L. Friis et al.

    Therapeutic experience with 947 epileptic out-patients in oxcarbazepine treatment

    Acta Neurol. Scand.

    (1993)
  • A.J. Gower et al.

    ucb LO59, a novel anti-convulsant drug: Pharmacological profile in animals

    Eur. J. Pharmacol.

    (1992)
  • S.K. Grant et al.

    Oxcarbazepine: A review of its pharmacology and therapeutic potential in epilepsy

    Drugs

    (1992)
  • J.P. Leach et al.

    Mutual pharmacokinetic interaction between remacemide and carbamazepine and phenytoin but not sodium valproate in epileptic patients

    Epilepsia

    (1994)
There are more references available in the full text version of this article.

Cited by (45)

  • Therapeutic monitoring of antiepileptic drugs

    2020, Handbook of Analytical Separations
    Citation Excerpt :

    Brivaracetam was recently approved for add-on in focal seizures. The most frequently reported side effects are drowsiness, tiredness, asthenia, and dizziness of mild to moderate severity with a dose-dependent increase in incidence, in addition to psychiatric symptoms as aggression in some patients [138,139]. Maybe this will be less pronounced with brivaracetam.

  • Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy

    2018, Epilepsy and Behavior
    Citation Excerpt :

    The main advantages of newer-generation AEDs, compared to conventional ones, are as follows: unique mechanisms of action, broad spectrum of action, similar efficacy, better pharmacokinetic characteristics (linear pharmacokinetics, lacking or lower enzyme induction, lower serum proteins binding, lower potential for drug interactions), better safety, and tolerability [1–13]. Effectiveness of all newer-generation AEDs as add-on treatment in patients with focal seizures has been confirmed by results from double-blind, randomized placebo-controlled, open prospective, and retrospective studies [14–43]. Some newer-generation AEDs have been proven as effective in generalized onset tonic–clonic seizures (lamotrigine, levetiracetam, topiramate, oxcarbazepine), atonic seizures (lamotrigine), absences (lamotrigine, topiramate), myoclonic seizures (lamotrigine, levetiracetam, topiramate), West syndrome, and Lennox–Gastaut syndrome (lamotrigine, topiramate, levetiracetam) [44–66].

  • A unified approach for detection of induced epileptic seizures in rats using ECoG signals

    2013, Epilepsy and Behavior
    Citation Excerpt :

    Epilepsy is a neurological disease that directly affects 50 million people worldwide [57]. In about two thirds of patients with epilepsy, seizures can be satisfactorily controlled with currently available antiepileptic drugs [58]. Another 8% can benefit from epilepsy surgery.

  • Chapter 9 Therapeutic drug monitoring of antiepileptic drugs

    2004, Handbook of Analytical Separations
    Citation Excerpt :

    Levetiracetam is effective in the treatment of partial seizures with or without generalisation to tonic clonic seizures [173]. The most frequently reported side effects are drowsiness, tiredness, asthenia, and dizziness of mild to moderate severity with a dose dependent increase in incidence [174,175]. The relationship between levetiracetam serum concentrations and clinical effect has not been ascertained and consequently, the value of serum concentration measurements has not been established.

View all citing articles on Scopus
View full text